Skip to main content

Building Related Illness (BRI)/ Sick Building Syndrome (SBS)

BayBiotech.NET
Built environments both residential and non residential are subject to number of indoor air quality (IAQ) and Indoor environment (IE) problems that may cause acute symptoms, health risks or discomfort.
A frequent IAQ and IE investigations can determine the occurrence of BRI and provide with healthier work environment. This is of utmost importance for Pharmaceutical/ Life Sciences industry where the product is directly subject to the human usage.
Non residential buildings are more prone to BRI as there is a high volume of occupants coming from diverse geographical areas interact in an environment where the ventilation of the building is not directly under the occupants control.
Health hazard evaluation teams from the National Institute of Occupational Safety and Health (NIOSH) conducts the investigation upon request and provides with strategies to avoid the recurrence of the problem. Some of the risk factors that may be used to evaluate biological contaminants as potential causes of allergy/asthma/sinusitis are as follows:
1. Mold: active mold infestation on building material, building history of water damage, wet building site, musty odors, viable mold test results of >1000 CFU/m3 and total mold counts >10,000 S/m3.
2. Dust mites: damp interiors, > 2 ug/g mite allergen levels in floor dust samples.
3. Apart from dust mites and mold, bacterias are major contributors to indoor health hazards and some of the diseases caused due to them are Tuberculosis, Pneumonia, Diphtheria, Anthrax, Meningitis, Respiratory infections and wound infections.

Poor IAQ contributed by various identifiable factors may cause decreased work performance and may impose significant economic costs on employers. Thus, it is important to have a regular investigations planned to test the health of the buildings used for performing the work.

In the US, NIOSH has developed a protocol to serve the needs of its health hazard evaluation teams. Such a team consists of an industrial hygienist, an epidemiologist, and a technical person familiar with the operation and maintenance of building mechanical systems.

To find out more on the topic, you may want to follow the readings as under:

1. www.epa.gov
2. USEPA/ NIOSH, EPA/400/1-91/003, DHHS Publication No. 91-1141-1991.
3. Thad Godish, Indoor Environmental Quality, CRC Press LLC, 2001.

Comments

Popular posts from this blog

Available Total Quality Management Tools

BayBiotech.NET Total Quality Management (or TQM) is a management concept coined by W. Edwards Deming. One of the principal aims of TQM is to limit errors to 1 per 1 million units produced. There are several TQM tools available today to analyze and assess qualitative and quantitative data. These tools can be examined and used to enhance the overall quality of the procedures, products or the work environment. Some of the most common TQM tools in use today are Pie Charts and Bar Graphs, Histograms, Run charts, Pareto Charts, Force Field Analysis, Ishikawa or Fishbone Diagrams, Tree Diagrams, Brainstorming, Flow Charts, Plan-Do-Check-Act cycle and Scatter Diagrams. Proper integration and use of these tools ultimately assist in processing data such as identifying collecting policies, enhancing work flows, ensuring client satisfaction by surveying their needs and analyzing them accordingly and creating an overall high level of quality in all areas of your organization. Use and choice...

Group C (Treatment IND) Drugs

BayBiotech.NET Since 1976, National Cancer Institute (NCI) in agreement with FDA has established the Group C classification system to allow access to certain drugs for the cancer patients specifically falling under a category that adequate alternative therapy or if the available alternative therapy has significant toxic effects. Each Group C drug protocol specifies patient eligibility and drug use information. Group C drugs are provided only to properly trained physicians who have registered themselves with NCI using a special form to assure that their patient qualifies under guidelines - or protocols - for the drug. Physicians using drugs under Group C have no reporting requirements to the NCI other than the obligation to report adverse drug reactions. Group C drugs are provided free of charge, and the Centers for Medicare and Medicaid Services provides coverage for care associated with Group C therapy. Making Group C drugs available to the critically ill patients not only provi...

A Facility Inspection Checklist

BayBiotech.NET Whether you are a Quality Assurance/ Compliance personnel planning to make a visit for a facility inspection, this checklist will help you prepare an inspection report based on the information that might be required to collect about the facility during the inspection. This checklist may help you evolve different forms for the inspection in order to accumulate complete information about the facility: 1.General information (a) name of establishment inspected (b) date of inspection (c) name(s) of the inspector(s) (d) date of last inspection. 2.Type of inspection Comprehensive, concise, follow-up, special, investigative, announced, and unannounced. 3.Licensing (a) licensing of premises (b) person with supervisory role in establishments (c) adherence to licensing provisions. 4. Activities undertaken on premises manufacturing, wholesale, importation, export, retail, hospital, pharmacy, clinic, nursing and maternity homes. 5. Adequacy and suitability of pre...